Evidence map›Paper›PMID 36980851›Full record

ArticleGenes2023

Feasibility of Community Pharmacist-Initiated and Point-of-Care

Amar D Levens, Melina C den Haan, J Wouter Jukema, Mette Heringa, Wilbert B van den Hout, Dirk Jan A R Moes, Jesse J Swen

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Amar D LevensDepartment of Clinical Pharmacy & Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID 0000-0003-2107-4693
Melina C den HaanDepartment of Cardiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
J Wouter JukemaDepartment of Cardiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID 0000-0002-3246-8359
Mette HeringaSIR Institute for Pharmacy Practice and Policy, 2331 JE Leiden, The Netherlands.ORCID 0000-0001-8316-8148
Wilbert B van den HoutDepartment of Biomedical Data Sciences, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Dirk Jan A R MoesDepartment of Clinical Pharmacy & Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Jesse J SwenDepartment of Clinical Pharmacy & Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID 0000-0002-3965-5552
Leiden University Medical Center · NLSIR Institute for Pharmacy Practice and Policy · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tailoring antiplatelet therapy based on

Indexed as

Acute Coronary SyndromeCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsClopidogrelFeasibility StudiesGenotypeHumansPharmacistsPoint-of-Care SystemsPrasugrel HydrochlorideTicagrelorClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsTicagrelorclopidogrelCYP2C19dual antiplatelet therapyP2Y12 inhibitorpersonalized medicinepharmacogeneticspharmacogenomicspoint-of-care testing

Identifiers

PMID36980851
PMCPMC10048116
OpenAlexW4322503815

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read85
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.